Immunotherapy in renal cell carcinoma: latest evidence and clinical implications

Article Details

Authors
Matteo Santoni MD, Francesco Massari MD, Vincenzo Di Nunno MD, Alessandro Conti MD, Alessia Cimadamore MD, Marina Scarpelli MD, Rodolfo Montironi PhD, Liang Cheng PhD, Nicola Battelli MD, Antonio Lopez-Beltran PhD

Article Type
Editorial

DOI
10.7573/dic.212528

Related Articles

Article Page

Abstract

Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible favourable sequential therapy of these two classes of drugs) remains an open question at this moment. Several trials are currently underway to assess the combination of anti-programmed-death 1 (PD-1) or anti-PD-ligand(L)1 agents with other immunotherapies or with anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this editorial, we described the results of the most recent clinical trials on the use of immunotherapies in RCC and the emerging data on the research for reliable biomarkers of tumour response in this setting. In addition, we have focused on the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies for RCC patients.

Keywords: immunocheckpoint inhibitors, immunotherapy, PD-1, renal cell carcinoma, tyrosine kinase inhibitors.

Citation: Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez-Beltran A. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs in Context 2018; 7: 212528. DOI: 10.7573/dic.212528

Contributions: MS and FM conceived and designed the study and contributed equally to the preparation of the manuscript. VdN, ACo and ACi conducted the structured literature review. MSc, RM, LC, NB and ALB drafted the manuscript. All authors analysed and interpreted the data, critically revised successive drafts of the manuscript and have approved the final version.

Disclosure and potential conflicts of interest: The authors declare no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2018/06/dic.212528-COI.pdf

Copyright: Copyright © 2018 Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez- Beltran A. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez-Beltran A. https://doi.org/10.7573/dic.212528. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/immunotherapy-in-renal-cell-carcinoma-latest-evidence-and-clinical-implications

Correspondence: Matteo Santoni, MD, Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100, Macerata, Italy. mattymo@alice.it

Provenance: invited; externally peer reviewed.

Submitted: 9 March 2018; Peer review comments to author: 27 March 2018; Revised manuscript received: 11 April 2018; Accepted: 16 April 2018; Publication date: 5 June 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009.

For all manuscript and submissions enquiries, contact the Editorial office dic.editorial@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF